Collegeville, NJ, United States of America

John M Wigginton


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 84(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Immunotherapy: The Contributions of John M Wigginton

Introduction

John M Wigginton is a notable inventor based in Collegeville, NJ (US), recognized for his significant contributions to the field of immunotherapy. His work primarily focuses on developing antibodies that target the PD-L1 signaling pathway, which plays a crucial role in cancer treatment. With a patent portfolio that includes innovative methods for treating cancer, Wigginton's research has the potential to impact many lives.

Latest Patents

Wigginton holds a patent for "Antibodies that bind PD-L1 and uses thereof." This patent outlines a method for immunotherapy aimed at subjects afflicted with cancer. The method involves administering a composition that contains a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 pathway. Additionally, the patent describes a process for selecting suitable candidates for immunotherapy based on the expression levels of PD-L1 in tissue samples. The invention also includes rabbit monoclonal antibodies (mAbs) that specifically bind to PD-L1 antigens in formalin-fixed, paraffin-embedded (FFPE) tissue samples, along with an automated immunohistochemistry (IHC) method for assessing cell surface expression.

Career Highlights

Wigginton is currently associated with Bristol-Myers Squibb Company, a leading biopharmaceutical company known for its innovative therapies. His work at the company has allowed him to collaborate with other talented professionals in the field, further enhancing the development of cancer treatments.

Collaborations

Some of Wigginton's notable coworkers include John P Cogswell and Stacie M Goldberg. Their collaborative efforts contribute to the advancement of research and development in immunotherapy.

Conclusion

John M Wigginton's innovative work in the field of immunotherapy exemplifies the impact of targeted treatments in cancer care. His contributions, particularly in developing antibodies that inhibit the PD-1/PD-L1 signaling pathway, are paving the way for more effective cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…